Moshkevich Solomon sold $1.4M of NTRA
Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,419 shares of Natera, Inc. (NTRA) at an average of $409.77 ($388.20–$416.45, $1.40M total) across 12 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider sales of this size are routine but can trigger short‑term price dips, especially for biotech stocks where insider sentiment is closely watched.
Market read
The filing provides fresh data on insider activity, useful for short‑term traders monitoring biotech stocks.
What to watch
Potential upcoming FDA filing or partnership news not disclosed.
Background
Natera is a mid‑cap biotech specializing in prenatal and oncology diagnostics.
Ticker impact
Form 4 shows President Solomon Moshkevich sold $1.4M of Natera shares via a 10b5‑1 plan.
likely pressure as the market prices in the insider sell
A C‑level officer sold over 3,000 shares at $409 average price; such sales often prompt modest downside bias.
Market effects
Minimal impact on the broader genetic‑testing sector.
No significant regional effect.
Limited to investors tracking insider activity.
Counterpoint
The sale could be a routine liquidity event unrelated to fundamentals.
Key entities
- companyNatera, Inc.
Issuer of the Form 4 filing.
- personSolomon Moshkevich
President, Clinical Diagnostics at Natera.



